Skip to main content
Premium Trial:

Request an Annual Quote

Goran Ando, Eugene Davidov, Paul Fletcher, Elizabeth Hutt, Anne Kopf-Sill, John Todd, Harry Elias, Morton Topfer

Premium

Decode Genetics has appointed Celltech CEO Goran Ando to its board of directors.

Ando joined Celltech in 2003 from Pharmacia, where he was executive vice president and president of R&D. He was previously R&D director for Glaxo Group Research, and held senior clinical and medical positions at Astra, Bristol-Myers, and Pfizer.


Eugene Davidov has been appointed as director of the Yale Center for Genomics and Proteomics, and Paul Fletcher as director of the center’s chemical genomics screening facility.

Before coming to Yale, Davidov was a principal investigator at Beyond Genomics. Prior to that, he worked at Millennium Pharmaceuticals and Anadys Pharmaceuticals. Davidov holds a PhD in biochemistry from Clark University.

Fletcher joins Yale from Edison, NJ-based DGI BioTechnologies, where he was director of screening technologies. Fletcher holds a BS from the University of Delaware, an MS in biology and animal science from Clemson University, and a PhD in reproductive physiology and biochemistry from the University of Wyoming.


NuGen Technologies has made some new hires: Elizabeth Hutt has been appointed vice president of sales and service, Anne Kopf-Sill vice president of product development, and John Todd vice president of marketing for the San Carlos, Calif.-based company.

Hutt joins NuGen from Tripos, where she was vice president of sales and service. She also held sales management positions with Affymetrix. Hutt obtained an MS in business administration from Central Michigan University and a BA in chemistry from Michigan State University.

Prior to coming to NuGen, Kopf-Sill was vice president of new products at Caliper Technologies. She holds a PhD in chemical engineering from Stanford University.

Todd, before joining NuGen, was an independent business consultant for biotechnology firms. He obtained a PhD in biochemistry from the University of Southern California Medical Center.


Harry Elias will join the board of directors of Bio-Reference Laboratories, the company said last week. He replaces Morton Topfer, who stepped down as director and vice chairman of Bio-Reference for personal reasons. Elias is chairman of JVC Company of America.

Filed under

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.